Medical products company UFP Technologies (NASDAQ: UFPT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 4.1% year on year to $154.2 million. Its non-GAAP profit of $2.48 per share was 7.4% above analysts’ consensus estimates.

Is now the time to buy UFPT? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

UFP Technologies delivered results in line with Wall Street’s revenue expectations for Q1 and outperformed on adjusted profitability, driving a positive market reaction. Management attributed the quarter’s growth to strength in medical sales, particularly in robotic surgery, patient surfaces, and interventional segments, which offset declines in nonmedical areas like automotive. CEO Jeff Bailly highlighted the company’s ongoing shift away from nonmedical markets and the ramp-up of four new program launches as key contributors to performance. "Our revenue grew 4.1% with medical sales growing 5.9%," Bailly noted, while acknowledging start-up costs and temporary drags from inventory issues and labor inefficiencies.

Looking ahead, UFP Technologies’ guidance is anchored by anticipated growth in its newly launched medical programs and increased production capacity in the Dominican Republic and Asia-Pacific regions. Management expects the four new programs to become significant contributors in the second half of the year as start-up costs are absorbed and volumes ramp. CFO Ronald Lataille stated, "As the volume ramps up, we’ll be absorbing those [start-up] costs... by the second half of the year, I think it will be robust contributions from all three of those brand-new programs." The company also plans to address raw material inflation and further diversify through disciplined M&A activity.

Key Insights from Management’s Remarks

Management credited the quarter’s results to robust medical segment growth, continued program launches, and strategic moves to expand capacity and focus on core markets.

• Medical segment strength: Growth in the robotic surgery, patient surfaces & support, and interventional and surgical submarkets offset weakness in wound care and nonmedical segments. This focus on MedTech aligns with the company’s long-term strategy to move away from lower-growth nonmedical categories.
• New program launches underway: Four new programs—three newly developed and one transfer—are in the ramping phase. Management highlighted that three of these have already led customers to request double the initial capacity, indicating promising demand that should translate into revenue acceleration later in the year.
• Capacity expansion in the Dominican Republic: The company is adding new buildings in both Santiago and La Romana to support forecasted growth in patient surfaces & support and robotic surgery. Co-investments with customers in these locations are expected to help address increasing demand and operational efficiency.
• Labor inefficiencies and backlog management: Labor turnover at AJR, a subsidiary, continued to impact costs and operational efficiency, though management reported gradual improvement. Increased production in Santiago is helping relieve pressure at AJR, and progress is being made to transition toward a more efficient workforce.
• Disciplined M&A approach: While UFP Technologies reviewed multiple acquisition opportunities, management emphasized a focus on strategic fit and valuation discipline. All recent acquisitions are performing well, and the company continues to see acquisition-driven growth as a meaningful part of its future, even as some opportunities are delayed or competitive.

Drivers of Future Performance

Management expects future growth to be driven by the ramp-up of new medical programs, expanded production capacity, and ongoing M&A activity, tempered by cost headwinds and market transitions.

• Medical program ramp-up: The company anticipates revenue growth to accelerate in the second half of the year as the four new medical programs move beyond the start-up phase. These programs are expected to benefit from existing customer requests for increased capacity, supporting higher volumes and improved profitability over time.
• Capacity additions and global expansion: UFP Technologies is investing in new buildings in the Dominican Republic and planning for additional capacity in the Asia-Pacific region. Management believes these investments will help address growing demand in the robotic surgery and patient surfaces segments and better position the company in key global markets.
• Margin headwinds and risk management: Management highlighted ongoing efforts to pass through raw material cost increases driven by oil price volatility and geopolitical factors. At the same time, they expect to see margin benefits from reduced tariffs and vendor credits, though labor inefficiencies and potential delays in customer program adoption remain risks to watch.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be monitoring (1) the successful ramp-up and revenue contribution from the four newly launched medical programs, (2) the operational impact of expanded production capacity in the Dominican Republic and initial plans for Asia-Pacific, and (3) improvements in labor efficiency and backlog reduction at AJR. Progress in these areas, along with ongoing acquisition activity, will be key markers for execution against UFP Technologies’ growth strategy.

UFP Technologies currently trades at $208.58, up from $192.55 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.